These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3555064)

  • 1. Efficacy of ciprofloxacin in animal models of infection.
    Andriole VT
    Am J Med; 1987 Apr; 82(4A):67-70. PubMed ID: 3555064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the efficacy of ciprofloxacin in animal models of infection.
    Andriole VT
    Am J Med; 1989 Nov; 87(5A):32S-34S. PubMed ID: 2589379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia.
    Sande MA; Brooks-Fournier RA; Gerberding JL
    Am J Med; 1987 Apr; 82(4A):63-6. PubMed ID: 3578331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of quinolones in experimental animal models of infections.
    Scheld WM
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):275-90. PubMed ID: 1864288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
    Davis C
    Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
    Lorian V; Pavletich K
    Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ciprofloxacin in the treatment of various bacterial infections.
    Phillips HL; Nolen TM; Hutchison J
    Ala Med; 1989 Apr; 58(10):28-32. PubMed ID: 2729030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.
    Louie TJ
    CMAJ; 1994 Mar; 150(5):669-76. PubMed ID: 8313286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critique of animal models in antibiotic research.
    Barza M
    Scand J Infect Dis Suppl; 1978; (14):109-17. PubMed ID: 279963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
    Brook I; Germana A; Giraldo DE; Camp-Hyde TD; Bolduc DL; Foriska MA; Elliott TB; Thakar JH; Shoemaker MO; Jackson WE; Ledney GD
    J Antimicrob Chemother; 2005 Dec; 56(6):1074-80. PubMed ID: 16239289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection.
    Haller I
    Am J Med; 1987 Apr; 82(4A):76-9. PubMed ID: 3578333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ciprofloxacin in refractory gram-negative bacillary infections.
    Bryant RE; Hartstein AI
    Int J Clin Pharmacol Res; 1987; 7(3):187-94. PubMed ID: 3596862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental models of sepsis and their clinical relevance.
    Poli-de-Figueiredo LF; Garrido AG; Nakagawa N; Sannomiya P
    Shock; 2008 Oct; 30 Suppl 1():53-9. PubMed ID: 18704008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The newer fluoroquinolones.
    O'Donnell JA; Gelone SP
    Infect Dis Clin North Am; 2004 Sep; 18(3):691-716, x. PubMed ID: 15308282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis.
    Guzek JP; Chacko D; Kettering JD; Wessels IF; Aprecio RM
    Cornea; 1994 Nov; 13(6):500-4. PubMed ID: 7842708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
    Ambrose PG; Bhavnani SM; Rubino CM; Louie A; Gumbo T; Forrest A; Drusano GL
    Clin Infect Dis; 2007 Jan; 44(1):79-86. PubMed ID: 17143821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of clinical experience with ciprofloxacin.
    Ball AP
    Eur J Clin Microbiol; 1986 Apr; 5(2):214-9. PubMed ID: 3013631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up therapy with ciprofloxacin in severe infection, an alternative to parenteral treatment.
    Bassaris HP; Chrysanthopoulos CJ; Skouelis AT; Starakis JC
    J Chemother; 1989 Jul; 1(4 Suppl):676-7. PubMed ID: 16312588
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antimicrobial activity of ciprofloxacin and netilmicin compared to various antibiotics in Lome, Togo].
    Dagnra AY; Prince-David M; Hounkpati A
    Sante; 2001; 11(1):63-6. PubMed ID: 11313234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.